		DAY 3: Wednesday, June 8, 2016	
		Symposium II	
		Animal Models and Translational Research	
8:15 - 8:30		**Breakfast**	
8:30 - 8:35		**Welcome speech by Dr. Pnina Brodt, Session Chair**	
8:35 - 9:15		**Dr. Andrew Kung, Columbia University, USA** Use of genomics and patient-derived xenograft models to realize the promise of personalized cancer medicine	**In vivo models, combinations and Drug Response**
9:15 - 9:55		**Dr. Paul Haluska, Merck Research Institute, USA** Ovarian avatars: Of mice and (wo)men… and personalized therapy	
9:55 -10:35		**Dr. Marcel Bally, BC Cancer Agency, Canada** Drug formulation strategies to capture the benefits of drug combinations arising from chemical synthetic lethal screens	
10:35 - 11:05		**Panel Discussion**	

11:05 - 13:35		**Short presentation series**	
13:35 - 14:15		**Welcome Speech by Dr. John Dibattista, Session Chair**	**Current and new Drug Development: translational research**
14:15 - 15:00		**Dr. Uri Saragovi, McGill University, Canada** Challenges in academic translational research	
15:00 - 15:40		**Dr. Rima Al-Awr, University of Toronto, Canada** Discovery and Optimization of Small Molecule Antagonists of the WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)	
15:40-16:05		**Panel Discussion**	

Symposium II: June 8, 2016: Animal models and translational research

Dr. Paul Haluska, Global Director of Scientific Affairs, Merck Research Laboratories

Dr. Haluska is a medical oncologist with a doctorate in Molecular Pharmacology. He obtained his B.S. in Biochemistry at Indiana University, after which he went on to complete an M.D., Ph.D., combined program at Robert Wood Johnson Medical School/Rutgers/Cancer Institute of New Jersey. Following completion of medical school, Dr. Haluska went on to a residency in internal medicine and fellowship in medical oncology at the Mayo Clinic in Rochester, Minnesota. Prior to joining Merck in April of 2015, Dr. Haluska was the Director of the Phase I Program at the Mayo Clinic and was the Principal Investigator of the UM1 Early Phase Trial Grant from the NCI for Mayo. He has served on the NCI Investigational Drug Steering Committee, the Alliance cooperative group Experimental Therapeutics Committee and continues to serve as faculty for the ESMO/AACR/EORTC Clinical Research Workshop in Flims, Switzerland. He also led an R01-funded laboratory the developed the largest known collection of ovarian patient-derived xenografts, where over 350 individual patient tumor are immortalized for novel drug development in immunocompromised mice. In addition to his own independently-funding, this work has led to multiple collaborative funding mechanisms including the Mayo Clinic Ovarian SPORE, a Program Project Development Grant and a Stand Up To Cancer Dream Team Award. His expertise in translational mouse modeling has led to his current role as Chair of the Mouse Models and Translation Research Study Section for NIH. Dr. Haluska has also had extensive experience in clinical and preclinical investigations in targeting insulin-like growth factor signaling. Dr. Haluska's clinical expertise in ovarian cancer has also earned him leadership roles, such as membership on the GOG Developmental Therapeutics Committee and ASCO Gynecological Cancer Track Scientific Program Committee.

Dr. Andrew L. Kung, M.D., Ph.D., Professor of Peditrics, Chief of Pediatrich Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, USA

Dr. Andrew L. Kung is the Robert and Ellen Kapito Professor of Pediatrics and Chief of the Division of Pediatric Hematology, Oncology and Stem Cell Transplantation at Columbia University Medical Center and NewYork-Presbyterian/Morgan Stanley Children's Hospital. Dr. Kung oversees the clinical and research programs of the Division, with the dual goal of providing outstanding care for patients today while developing the next generation of therapies for future patients. Working with his colleagues, Dr. Kung takes a cross-disciplinary approach to translational research, integrating molecular biology, genomics, cell biology, laboratory models, and drug development. The research in his lab focuses on identifying new targets for anticancer drugs, the genomics of cancer, and the development of innovative therapies that target the determinants of

cancer growth. Dr. Kung has led the development of a comprehensive precision medicine program for children with cancer and blood disorders. Through the Precision in Pediatric Sequencing (PIPseq) program, every child treated in the Division is offered genomic sequencing of his or her cancer. Coupled with the Developmental Therapeutics Program and a robust selection of clinical trials, the Division endeavors to use the technologies and therapies of tomorrow to create personalized treatment plans for each patient being cared for today.

Dr. Marcel B. Bally, Professor, Head, Experimental Therapeutics, BC Cancer Agency

Marcel B. Bally, Head and Distinguished Scientist (Experimental Therapeutics; BC Cancer Agency), Professor (Pathology and Laboratory Medicine, UBC), Adjunct Professor (Pharmaceutical Sciences, UBC), and Chair (Pharmacology and Toxicology Division, Centre for Drug Research and Development). Dr. Bally is an authority in drug delivery, anti-cancer drug combinations and drug evaluation in animal models of disease. He has published 200 scientific articles, 136 published abstracts and 18 book chapters. These works have been cited over 15,000 times. He has trained 31 PDFs, 21 PhD students and 4 MSc students and has been a PI or Co-PI on grants valued in aggregate at more than $50,000,000. Dr. Bally holds patents/patent applications which are linked to two FDA/Health Canada approved anticancer drugs, one product in late stage development and several others in early stage clinical trials and preclinical development. This would include (i) Myocet, a liposomal formulation of doxorubicin approved for use in Europe for treatment of metastatic breast cancer; (ii) Marqibo® (vincristine sulfate injection, OPTISOME™), a liposomal vincristine formulation for treatment of Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia which received US FDA approval in 2012; (iii) CPX-1; a first in class drug combination product comprising a fixed ratio liposomal formulation of Irinotecan (CPT-11)/Floxuridine (FUDR); and (iv) CPX-351; a first in class drug combination product comprising of cytarabine and daunorubicin. CPX- 351 is being evaluated in Phase III clinical studies in patients with acute myeloid leukemia.

Dr. Uri Saragovi, Professor of Pharmacology and Therapeutics, McGill University

Uri Saragovi, PhD, is a professor of Pharmacology and Therapeutics at McGill University, and cofounder of Mimetogen Pharmaceuticals. Dr. Saragovi's research focuses on understanding macromolecular structure function relationships, particularly in receptor-ligand interactions. His group applies this knowledge to experimental therapeutics and to translational research in cancer and neurodegenerative diseases. Dr. Saragovi has contributed towards the development of protein mimicry technologies. His group has developed mimics of antibodies, cellular receptors, and polypeptide growth factors (antagonists and agonists). More recently, Dr. Saragovi's group has also developed a technology where therapeutic agents can be selectively delivered to the target cell. His laboratory has a strong translational component, and many of the pharmacological lead agents discovered by them have entered clinical development in humans.

Dr. Rima Al-Awar, Director Drug Discovery Program, Ontario Institute for Cancer

Research Dr. Al-awar earned a PhD in synthetic organic chemistry from North Carolina State University working on Lycopodium Alkaloids and did a post-doctoral fellowship focused on natural products synthesis at the University of North Carolina at Chapel Hill prior to joining Eli Lilly and Company in 1995. While at Lilly, she was an active medicinal chemist in the oncology area working in multidisciplinary teams on the antimicrotubule agent Cryptophycin and later on several kinase focused efforts. In 2002, while at Lilly, Dr. Al-awar took on administrative responsibilities as Head in Discovery Chemistry Research and Technologies and later as Head, Route Selection, in Chemical Product Research and Development prior to joining the Ontario Institute for Cancer Research as Director of the Drug Discovery Program in July 2008.